Russell Investments Group Ltd. Purchases 314,747 Shares of Zoetis Inc. $ZTS

Russell Investments Group Ltd. boosted its position in Zoetis Inc. (NYSE:ZTS) by 54.4% during the second quarter, Holdings Channel reports. The institutional investor owned 893,500 shares of the company’s stock after purchasing an additional 314,747 shares during the quarter. Russell Investments Group Ltd.’s holdings in Zoetis were worth $64,441,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Prosperity Bancshares Inc bought a new position in shares of Zoetis during the 4th quarter worth approximately $25,000. Cassaday & Co Wealth Management LLC bought a new stake in Zoetis during the 1st quarter worth about $28,000. Elyxium Wealth LLC acquired a new position in shares of Zoetis during the 4th quarter worth about $32,000. Root Financial Partners LLC grew its holdings in shares of Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after acquiring an additional 103 shares in the last quarter. Finally, Wellington Grp LLC grew its holdings in shares of Zoetis by 6,675.0% in the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after acquiring an additional 267 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 2.9%

Shares of ZTS stock opened at $73.64 on Friday. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The firm’s 50-day moving average is $76.30 and its 200-day moving average is $99.01. The stock has a market cap of $30.43 billion, a price-to-earnings ratio of 12.13, a PEG ratio of 1.28 and a beta of 0.74. Zoetis Inc. has a 52-week low of $71.45 and a 52-week high of $160.48.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same period last year, the business posted $1.76 EPS. Zoetis’s revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.19 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is presently 34.93%.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Citigroup dropped their target price on Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Piper Sandler lowered their price target on Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a research report on Monday, August 10th. HSBC dropped their price objective on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Finally, William Blair reissued a “market perform” rating on shares of Zoetis in a report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $109.62.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.